Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. Currently it is undergoing Phase 1 clinical trials at City of Hope in glioblastoma. The company was founded by Paul A. Hopper on Feburary 2, 2020 and is headquartered in Carlton South, Australia.